BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee YI, Park Y, Park SJ, Kim TI, Kim WH, Cheon JH. Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis. Gut Liver 2021;15:232-42. [PMID: 32616683 DOI: 10.5009/gnl19433] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Kim ES. Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis? Gut Liver 2021;15:149-50. [PMID: 33716221 DOI: 10.5009/gnl210098] [Reference Citation Analysis]
2 Kim ES, Kim SK, Park DI, Kim HJ, Lee YJ, Koo JS, Kim ES, Yoon H, Lee JH, Kim JW, Shin SJ, Kim HW, Kim HS, Park YS, Kim YS, Kim TO, Lee J, Choi CH, Han DS, Chun J, Kim HS; IBD Research Group in the Korean Association for the Study of Intestinal Diseases. Comparison of the Pharmacokinetics of CT-P13 Between Crohn's Disease and Ulcerative Colitis. J Clin Gastroenterol 2022. [PMID: 35470308 DOI: 10.1097/MCG.0000000000001715] [Reference Citation Analysis]
3 Macaluso FS, Maida M, Grova M, Crispino F, Teresi G, Orlando A, Orlando A. Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomized controlled trials to real-world experience. Therap Adv Gastroenterol 2021;14:17562848211010668. [PMID: 33995582 DOI: 10.1177/17562848211010668] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Sassaki LY, Magro DO, Saad-hossne R, Baima JP, Flores C, Correia LM, Celani LMS, De Abreu Ferrari MDL, Zacharias P, Feitosa MR, Dos Santos CHM, De Freitas Lins Neto MA, Quaresma AB, De Lima Junior SF, De Vasconcelos GBS, Cassol OS, Dos Santos Pinto A, Kurachi G, Goncalves Filho FDA, Gasparini RG, Furlan TK, Catapani WR, Coy CSR, De Souza Menegassi V, Colombo MM, Fróes RDSB, Teixeira FV, Moraes AC, Santana GO, Parente JML, Vilela EG, Queiroz NSF, Kotze PG; GEDIIB (Brazilian Study Group of IBD). Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB). BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02341-7] [Reference Citation Analysis]